medigraphic.com
ISSN 1561-2945 (Print)

2022, Number 2

Next >>

Revista Cubana de Cirugía 2022; 61 (2)

Clinical epidemiological characterization of Peyronie's disease patients infiltrated with mononuclear cells

Lamelas TAA, Lamelas ÁAR, Gámez PA, González PY, Rodríguez OCÁ, Álvarez MM

Language: Spanish
References: 16
Page: 1-16
PDF size: 490.07 Kb.


ABSTRACT

Introduction: Peyronie's disease is rare and involves middle-aged men.
Objective: To characterize the clinical and epidemiological aspects of patients with Peyronie's disease infiltrated with mononuclear cells.
Methods: An observational, analytical, prospective longitudinal study was carried out at the "Comandante Pinares" General Teaching Hospital from June 2015 to May 2018, with a sample of 159 patients. The variables of age, skin color, etiological factors, curvature and deviation of the penis, as well as symptoms and signs, were controlled.
Results: The largest number of patients corresponded to the age of 50-59 years, white skin, degrees of curvature between 20o and 39o. After treatment, 115 patients were found to have curvature less than 20o and dorsal deviation. The most frequent cause of penile microtrauma is during sexual intercourse or in the flaccid state of the penis (105/159). Diabetes mellitus and arterial hypertension, with 59.7 and 30.8%, respectively, are the most frequent etiological factors; the symptoms and signs were pain and curvature, 115 patients presented absence of pain when comparing the mean at the end of the treatment, being significant (p= 0.0000).
Conclusions: Peyronie's disease is frequent in patients of the fifth decade of life, with white skin color. The most frequent cause are microtraumas in sexual activity, diabetes mellitus and arterial hypertension as personal pathological antecedents. There is improvement of the symptoms in patients infiltrated with mononuclear cells.


REFERENCES

  1. Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie's Disease Questionnaire (PDQ). J Sex Med. 2015;12(4):1072-9. 20. DOI: https://doi.org/10.1111/jsm.128381.

  2. Chung E, Ralph D, Kagioglu A. Evidence-Based Management guidelines on Peyronie's Disease. J Sex Med. 2016;13(6):905-23. DOI: https://doi.org/10.1016/j.jsxm.2016.04.0622.

  3. Piamo MAJ, García RMA. Uso de la elastosonografía en el diagnóstico de la enfermedad de Peyronie. Acta Med Cent. 2020 [acceso 09/09/2021];14(2):257-67. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=95620 3.

  4. Ziegelmann MJ, Bajic P, Levine LA. Peyronie's disease: contemporary evaluation and management. Int J Urol. 2020;27(6):504-16. DOI:https://doi.org/10.1111/iju.142304.

  5. Alonso-Isa M, García-Gómez B, García-Rojo E, Medina-Polo J, Manfredi C, Rodríguez-Antolín A, et al. Implante de prótesis de pene en la era COVID. Seguimiento tras la cirugía y manejo de complicaciones. Rev. Int. de Andrología. 2022;20(1):62-7. DOI:https://doi.org/10.1016/j.androl.2020.10.0025.

  6. Pérez Sánchez Y, Quintero Larróvere M. Tratamiento seriado con plasma rico en plaquetas en rejuvenecimiento facial. Cambios histopatológicos y clínicos. Cir. Plás. Iberolatinoam. 2020;46(4):421-40. DOI: https://dx.doi.org/10.4321/s0376-789220200005000066.

  7. Cocci A, Russo G, Salonia A, Cito G, Regis F, Polloni G, et al. Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study. J Sex Med. 2018;15(5):716-21. DOI:https://doi.org/10.1016/j.jsxm.2018.03.0847.

  8. Nguyen H, Anaissie J, DeLay K, Yafi F, Sikka S, Hellstrom W, et al. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease. J Sex Med. 2017;14(10):1220-5. DOI:https://doi.org/10.1016/j.jsxm.2017.08.0088.

  9. Sánchez Fernández CM, Morales Font D, Martín Suárez MA, Hernández Aise MI, Abreu Cuba EM, Domínguez Ruiz B, et al9. . Enfermedad de La Peyronié, un trastorno infradiagnosticado. Rev Méd Electrón. 2017[acceso 09/09/2018]39(1):84-90. Disponible en: Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/1455/3274. http://scielo.sld.cu/pdf/rme/v39n1/rme100117.pdf 9.

  10. Pedro Silva IE, Lamar Yins Y. Resultados del tratamiento en la Enfermedad de La Peyronié. Hospital Hermanos Ameijeiras: 2010-2016. Rev Cubana Urol. 2018[acceso 09/09/2018];7:e16. Disponible en: Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/373/368 10.

  11. González PY, Ramos FM, Alfonso RDM. Buenas prácticas de enfermería en pacientes con enfermedad de La Peyronié tratados con medicina regenerativa. RCU. 2018;7(Suppl:1):e25. [ Links ]

  12. Sangkum P. Research highlights on stem cell therapy for the treatment of Peyronie’s disease. Transl Androl Urol. 2016;5(3):363-5. DOI: 10.21037/tau.2016.03.14 [ Links ]

  13. Quintana Rodríguez M, Guzmán Mederos R, Fragas Valdés R. Eficacia y seguridad del implante de prótesis peneana maleable en pacientes con disfunción eréctil. Rev. Cubana Urol. 2020[acceso 05/07/2021];9(1):[aprox. 9 p.]. Disponible en: Disponible en: http://revurologia.sld.cu/index.php/rcu/article/view/531 13.

  14. Alwaal AHA, Lin CS, Lue TF. Prospects of stem cell treatment in benign urological diseases. Korean J Urol. 2015;56(4):257-65. DOI: 10.4111/kju.2015.56.4.257 [ Links ]

  15. Xu Y, Song YF, Lin ZX. Transplantation of muscle-derived stem cells plus biodegradable fibrin glue restores the urethral sphincter in a pudendal nerve-transected rat model. Braz J Med Biol Res. 2010;43(11):1076-83. DOI:https://doi.org/10.1590/S0100-879X201000750011215.

  16. Hernández Ramírez P. ¿Es realmente útil el tratamiento con la terapia celular regenerativa? Rev Cubana Hematol Inmunol Hemoter. 2017[acceso 11/01/2018];33(1):1-13. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892017000100005&lng=es 16.




2020     |     www.medigraphic.com